Vytrus Biotech (VYT) Stock Overview
Develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
VYT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Vytrus Biotech, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €8.10 |
| 52 Week High | €8.95 |
| 52 Week Low | €2.12 |
| Beta | 0.032 |
| 1 Month Change | 28.57% |
| 3 Month Change | 33.88% |
| 1 Year Change | 271.56% |
| 3 Year Change | 139.65% |
| 5 Year Change | n/a |
| Change since IPO | 275.00% |
Recent News & Updates
Investors Still Waiting For A Pull Back In Vytrus Biotech, S.A. (BME:VYT)
Oct 29
After Leaping 29% Vytrus Biotech, S.A. (BME:VYT) Shares Are Not Flying Under The Radar
Jul 22Recent updates
Investors Still Waiting For A Pull Back In Vytrus Biotech, S.A. (BME:VYT)
Oct 29After Leaping 29% Vytrus Biotech, S.A. (BME:VYT) Shares Are Not Flying Under The Radar
Jul 22Returns Are Gaining Momentum At Vytrus Biotech (BME:VYT)
Apr 29Pinning Down Vytrus Biotech, S.A.'s (BME:VYT) P/E Is Difficult Right Now
Sep 26Shareholder Returns
| VYT | ES Personal Products | ES Market | |
|---|---|---|---|
| 7D | -4.7% | 4.2% | 2.6% |
| 1Y | 271.6% | 1.2% | 33.1% |
Return vs Industry: VYT exceeded the Spanish Personal Products industry which returned 1% over the past year.
Return vs Market: VYT exceeded the Spanish Market which returned 31% over the past year.
Price Volatility
| VYT volatility | |
|---|---|
| VYT Average Weekly Movement | 9.6% |
| Personal Products Industry Average Movement | 4.7% |
| Market Average Movement | 3.1% |
| 10% most volatile stocks in ES Market | 6.5% |
| 10% least volatile stocks in ES Market | 0.5% |
Stable Share Price: VYT's share price has been volatile over the past 3 months compared to the Spanish market.
Volatility Over Time: VYT's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Spanish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 37 | Albert Font | www.vytrus.com |
Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. The company offers Clarivine that activates skin’s regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Longa that improves density in hair, eyebrows, and eyelashes; and Luminia Granatum that brightens skin, whitens dark spots, evens skin tone, and protects against oxidative stress. It also provides Baolift that improves muscle tone and facial complexion; Elaya Renova that boosts hair tensegrity; Kannabia Sense, a prebiotic treatment that stimulates the skin microbiota to produce an in-situ postbiotic cocktail; Quora Noni to avoid the attack of skin harmful bacteria; Centella Reversa for facial complexion improvement; and Arabian Cotton to protect and repair cell structures against sun damage.
Vytrus Biotech, S.A. Fundamentals Summary
| VYT fundamental statistics | |
|---|---|
| Market cap | €60.95m |
| Earnings (TTM) | €1.95m |
| Revenue (TTM) | €8.09m |
Is VYT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VYT income statement (TTM) | |
|---|---|
| Revenue | €8.09m |
| Cost of Revenue | €765.90k |
| Gross Profit | €7.32m |
| Other Expenses | €5.37m |
| Earnings | €1.95m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.26 |
| Gross Margin | 90.53% |
| Net Profit Margin | 24.15% |
| Debt/Equity Ratio | 15.9% |
How did VYT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/26 09:50 |
| End of Day Share Price | 2025/11/26 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vytrus Biotech, S.A. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Marisa Luisa Mazo Fajardo | GVC Gaesco Valores |